Practical Radiation Oncology最新文献

{"title":"Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline","authors":"Danielle N. Margalit MD, MPH ,&nbsp;Christopher J. Anker MD ,&nbsp;Michalis Aristophanous PhD ,&nbsp;Musaddiq Awan MD ,&nbsp;Gopal K. Bajaj MD, MBA ,&nbsp;Lisa Bradfield BA ,&nbsp;Joseph Califano MD ,&nbsp;Jimmy J. Caudell MD, PhD ,&nbsp;Christina H. Chapman MD, MS ,&nbsp;Adam S. Garden MD ,&nbsp;Paul M. Harari MD ,&nbsp;Amanda Helms MLIS ,&nbsp;Alexander Lin MD ,&nbsp;Ellie Maghami MD ,&nbsp;Ranee Mehra MD ,&nbsp;Lance Parker MBA ,&nbsp;Yelizaveta Shnayder MD ,&nbsp;Sharon Spencer MD ,&nbsp;Paul L. Swiecicki MD ,&nbsp;Jillian Chiaojung Tsai MD, PhD ,&nbsp;David J. Sher MD, MPH","doi":"10.1016/j.prro.2024.05.007","DOIUrl":"10.1016/j.prro.2024.05.007","url":null,"abstract":"<div><h3>Purpose</h3><p>Human Papilloma Virus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is a distinct disease from other head and neck tumors. This guideline provides evidence-based recommendations on the critical decisions in its curative treatment, including both definitive and postoperative radiation therapy (RT) management.</p></div><div><h3>Methods</h3><p>ASTRO convened a task force to address 5 key questions on the use of RT for management of HPV-associated OPSCC. These questions included indications for definitive and postoperative RT and chemoradiation; dose-fractionation regimens and treatment volumes; preferred RT techniques and normal tissue considerations; and posttreatment management decisions. The task force did not address indications for primary surgery versus RT. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for grading evidence quality and recommendation strength.</p></div><div><h3>Results</h3><p>Concurrent cisplatin is recommended for patients receiving definitive RT with T3-4 disease and/or 1 node &gt;3 cm, or multiple nodes. For similar patients who are ineligible for cisplatin, concurrent cetuximab, carboplatin/5-fluorouracil, or taxane-based systemic therapy are conditionally recommended. In the postoperative setting, RT with concurrent cisplatin (either schedule) is recommended for positive surgical margins or extranodal extension. Postoperative RT alone is recommended for pT3-4 disease, &gt;2 nodes, or a single node &gt;3 cm. Observation is conditionally recommended for pT1-2 disease and a single node ≤3 cm without other risk factors. For patients treated with definitive RT with concurrent systemic therapy, 7000 cGy in 33 to 35 fractions is recommended, and for patients receiving postoperative RT without positive surgical margins and extranodal extension, 5600 to 6000 cGy is recommended. For all patients receiving RT, intensity modulated RT over 3-dimensional techniques with reduction in dose to critical organs at risk (including salivary and swallowing structures) is recommended. Reassessment with positron emission tomography-computed tomography is recommended approximately 3 months after definitive RT/chemoradiation, and neck dissection is recommended for convincing evidence of residual disease; for equivocal positron emission tomography-computed tomography findings, either neck dissection or repeat imaging is recommended.</p></div><div><h3>Conclusions</h3><p>The role and practice of RT continues to evolve for HPV-associated OPSCC, and these guidelines inform best clinical practice based on the available evidence.</p></div>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"14 5","pages":"Pages 398-425"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1879850024001395/pdfft?md5=a1d7e2c5f4c1194bde3ba35988eed051&pid=1-s2.0-S1879850024001395-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increase in Hypofractionated Radiation Therapy Among Patients with Invasive Breast Cancer or Ductal Carcinoma In Situ: Who is Left Behind?","authors":"","doi":"10.1016/j.prro.2024.04.010","DOIUrl":"10.1016/j.prro.2024.04.010","url":null,"abstract":"<div><h3>Purpose</h3><p><span>We aimed to update the trend of hypofractionated whole-breast irradiation (HF-WBI) use over time in the US and examine factors associated with lack of HF-WBI adoption for patients with early-stage invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS) undergoing a </span>lumpectomy.</p></div><div><h3>Methods and Materials</h3><p>Among patients who underwent a lumpectomy, we identified 928,034 patients with early-stage IBC and 330,964 patients with DCIS in the 2004 to 2020 National Cancer Database. We defined HF-WBI as 2.5-3.33 Gy/fraction to the breast and conventionally fractionated WBI as 1.8-2.0 Gy/fraction. We evaluated the trend of HF-WBI utilization using a generalized linear model with the log link and binomial distribution. Factors associated with HF-WBI utilization were assessed using multivariable logistic regression in patients diagnosed between 2018 and 2020.</p></div><div><h3>Results</h3><p>Among patients with IBC, HF-WBI use has significantly increased from 0.7% in 2004 to 63.9% in 2020. Similarly, HF-WBI usage among patients with DCIS has also increased significantly from 0.4% in 2004 to 56.6% in 2020. Black patients with IBC were less likely than White patients to receive HF-WBI (adjusted odds ratio [AOR] 0.81; 95% CI, 0.77-0.85). Community cancer programs were less likely to administer HF-WBI to patients with IBC (AOR, 0.80; 95% CI, 0.77-0.84) and to those with DCIS (AOR, 0.87; 95% CI, 0.79-0.96) than academic/research programs. Younger age, positive nodes, larger tumor size, low volume programs, and facility location were also associated with lack of HF-WBI adoption in both patient cohorts.</p></div><div><h3>Conclusions</h3><p>HF-WBI utilization among postlumpectomy patients has significantly increased from 2004 to 2020 and can finally be considered standard of care in the US. We found substantial disparities in adoption within patient and facility subgroups. Reducing disparities in HF-WBI adoption has the potential to further alleviate health care costs while improving patients’ quality of life.</p></div>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"14 5","pages":"Pages e305-e323"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Custom-Trained Deep Learning-Based Auto-Segmentation for Male Pelvic Iterative CBCT on C-Arm Linear Accelerators","authors":"","doi":"10.1016/j.prro.2024.01.006","DOIUrl":"10.1016/j.prro.2024.01.006","url":null,"abstract":"<div><h3>Purpose</h3><p><span>The purpose of this investigation was to evaluate the clinical applicability of a commercial artificial intelligence–driven deep learning auto-segmentation (DLAS) tool on enhanced iterative </span>cone beam computed tomography (iCBCT) acquisitions for intact prostate and prostate bed treatments.</p></div><div><h3>Methods and Materials</h3><p><span><span>DLAS models were trained using 116 iCBCT data sets with manually delineated organs at risk (bladder, femoral heads, and rectum) and target volumes (intact prostate and prostate bed) adhering to institution-specific contouring guidelines. An additional 25 intact prostate and prostate bed iCBCT data sets were used for model testing. Segmentation accuracy relative to a reference structure set was quantified using various geometric comparison metrics and qualitatively evaluated by trained physicists and physicians. These results were compared with those obtained for an additional DLAS-based model trained on planning </span>computed tomography (pCT) data sets and for a </span>deformable image registration (DIR)-based automatic contour propagation method.</p></div><div><h3>Results</h3><p><span>In most instances, statistically significant differences in the Dice similarity coefficient (DSC), 95% directed Hausdorff distance, and mean surface distance metrics were observed between the models, as the iCBCT-trained DLAS model outperformed the pCT-trained DLAS model and DIR-based method for all organs at risk and the intact prostate target volume. Mean DSC values for the proposed method were </span><span><math><mo>≥</mo></math></span><span>0.90 for these volumes of interest. The iCBCT-trained DLAS model demonstrated a relatively suboptimal performance for the prostate bed segmentation, as the mean DSC value was &lt;0.75 for this target contour. Overall, 90% of bladder, 93% of femoral head, 67% of rectum, and 92% of intact prostate contours generated by the proposed method were deemed clinically acceptable based on qualitative scoring, and approximately 63% of prostate bed contours required moderate or major manual editing to adhere to institutional contouring guidelines.</span></p></div><div><h3>Conclusions</h3><p>The proposed method presents the potential for improved segmentation accuracy and efficiency compared with the DIR-based automatic contour propagation method as commonly applied in CBCT-based dose evaluation and calculation studies.</p></div>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"14 5","pages":"Pages e383-e394"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139703929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Srimad Bhagavata Purana Book X: A Lesson in the Beauty of the Midnight Sky","authors":"","doi":"10.1016/j.prro.2024.02.005","DOIUrl":"10.1016/j.prro.2024.02.005","url":null,"abstract":"","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"14 5","pages":"Pages 371-372"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140271731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of Clinical-Pathological Parameters for Exclusion of BRCA1/2 Mutation Carriers as Candidates for Partial Breast Irradiation","authors":"Rinat Bernstein-Molho MD ,&nbsp;Narmeen Abu-Shehada MSc ,&nbsp;Einav Nili Gal-Yam MD, PhD ,&nbsp;Douglas Zippel MD ,&nbsp;Tehillah Menes MD ,&nbsp;Miri Sklair-Levy MD ,&nbsp;Shira Galper MD ,&nbsp;Orit Kaidar-Person MD","doi":"10.1016/j.prro.2024.04.019","DOIUrl":"10.1016/j.prro.2024.04.019","url":null,"abstract":"<div><h3>Purpose</h3><p>Several international groups have published guidelines to identify low-risk breast cancer (BC) patients who are eligible for partial breast irradiation (PBI). These include the American Society for Radiation Oncology (ASTRO), the European Society for Radiotherapy and Oncology (ESTRO), and ESTRO subgroups such as the Intraoperative radiation (IORT) Task Force and Groupe Européen de Curiethérapie (GEC) -ESTRO. Only ASTRO guidelines recommend against the use of PBI in known carriers of germline pathogenic variants (PVs) in <em>BRCA1</em>/<em>2</em>. The aim of this study was to evaluate the proportion of BC patients, subsequently found to be <em>BRCA1/2</em> PV carriers who would be eligible for PBI based on clinical-pathologic criteria of the above-mentioned international guidelines.</p></div><div><h3>Methods and Materials</h3><p>Data were extracted from the medical records of consecutive BC <em>BRCA1/2</em> PV carriers treated at a single institution between 2006 and 2023. Data included patient demographics, tumor characteristics, treatment, and disease outcomes.</p></div><div><h3>Results</h3><p>Overall, 498 patients with 518 primary tumors were analyzed. Of these, 282 (12 of them with synchronous bilateral disease) presented with unknown genetic status at diagnosis and formed the study cohort. The median age at diagnosis was 42.7 years (range, 23.8-77.9). Based on the recent ASTRO guidelines (not including conditionally recommended criteria), 17 of 294 (5.8%) of the carriers had tumors that would be eligible for PBI, including 3 Her2-positive tumors and 5 patients diagnosed between ages 40 and 49 years. Using the ESTRO IORT and the ACROP-ESTRO PBI criteria, 9 of 294 (3%) would be eligible, whereas with the GEC-ESTRO low-risk criteria, 31 of 294 (10.5%) of the carriers would be eligible, and their intermediate risk criteria would increase eligibility for PBI by an additional 8.2% (overall 18.7%).</p></div><div><h3>Conclusions</h3><p>Using clinical-pathologic criteria published in international guidelines, 3% to 18% of <em>BRCA1/2</em> PV carriers will have tumors eligible for PBI. Therefore, especially in populations who are at high risk for being <em>BRCA1/2</em> PV carriers, we recommend adhering to stricter guidelines. In our cohort, ASTRO, ESTRO-IORT, and ESTRO PBI had the lowest probability of identifying <em>BRCA1/2</em> PV carriers as eligible for PBI.</p></div>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"14 5","pages":"Pages 435-442"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Regard to Ethan B. Ludmir et al","authors":"Sarah Akhtar MBBS,&nbsp;Maria Tariq MBBS, FCPS,&nbsp;Bareera Shamsi MBBS,&nbsp;Sehrish Abrar MBBS, FCPS,&nbsp;Bilal Mazhar Qureshi MBBS, FCPS,&nbsp;Asim Hafiz MBBS, FCPS,&nbsp;Nasir Ali MBBS, FCPS,&nbsp;Ahmed Nadeem Abbasi MBBS, FRCR","doi":"10.1016/j.prro.2024.03.006","DOIUrl":"10.1016/j.prro.2024.03.006","url":null,"abstract":"","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"14 5","pages":"Pages 464-465"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence: In Regard to Gogineni et al.","authors":"Laraib Khan MBBS,&nbsp;Maham Khan MBBS,&nbsp;Tooba Ali MBBS,&nbsp;Mariam Hina MBBS,&nbsp;Asim Hafiz MBBS, FCPS,&nbsp;Sehrish Abrar MBBS, FCPS,&nbsp;Nasir Ali MBBS, FCPS,&nbsp;Ahmed Nadeem Abbasi MBBS, FFRRCSI,&nbsp;Bilal Mazhar Qureshi MBBS, FCPS","doi":"10.1016/j.prro.2024.04.021","DOIUrl":"10.1016/j.prro.2024.04.021","url":null,"abstract":"","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"14 5","pages":"Page 468"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Update on H3K27M-altered Diffuse Midline Glioma: Diagnostic and Therapeutic Challenges in Clinical Practice","authors":"","doi":"10.1016/j.prro.2024.04.013","DOIUrl":"10.1016/j.prro.2024.04.013","url":null,"abstract":"<div><p><span>H3K27-altered diffuse midline glioma<span> (DMG H3K27-altered) is a relatively newly-designated WHO entity which primarily affects the midline structures of the central nervous system (CNS), including the </span></span>brainstem<span> (predominantly pontine region), thalamus<span>, midbrain, or spinal cord, and primarily affects children and young adults. Despite the proximity of these tumors to eloquent areas in the CNS, novel stereotactic approaches have facilitated the ability to obtain tissue diagnoses without significant morbidity, providing molecular diagnostic information in more than half of patients. Conventionally fractionated radiation therapy to a total dose of 54-60 Gy in 27-30 fractions and 24 Gy in 12 fractions play a crucial role in the definitive treatment of these tumors in the primary and salvage settings, respectively. Hypofractionated regimens may allow for accelerated treatment courses in selected patients without jeopardizing disease control or survival. The decision to add concurrent or adjuvant systemic therapy mainly relies on the physicians’ experience without solid evidence in the literature in favor of any particular regimen. Recently, novel agents, such as ONC201 have demonstrated promising oncologic outcomes in progressive/recurrent tumors and are currently under investigation in ongoing randomized trials. Given the scarcity of data and well-established guidelines due to the rare nature of the disease, we provide a contemporary overview on the molecular underpinnings of this disease entity, describe the role of radiotherapy and systemic therapy, and present practice management principles based on the published literature.</span></span></p></div>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"14 5","pages":"Pages 443-451"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to: Pashtan IM, Kosak T, Shin K-Y, et al. An Automated, Dynamic Radiation Oncology Prescription Checking System. Pract Radiat Oncol. 2024;14:343-352.","authors":"","doi":"10.1016/j.prro.2024.05.003","DOIUrl":"10.1016/j.prro.2024.05.003","url":null,"abstract":"","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"14 5","pages":"Page e416"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1879850024001061/pdfft?md5=9d43a29d39744b143c2487eca3387390&pid=1-s2.0-S1879850024001061-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adapt-On-Demand: A Novel Strategy for Personalized Adaptive Radiation Therapy for Locally Advanced Lung Cancer","authors":"","doi":"10.1016/j.prro.2024.02.007","DOIUrl":"10.1016/j.prro.2024.02.007","url":null,"abstract":"<div><h3>Purpose</h3><p><span>Real-time adaptation of thoracic radiation plans is compelling because offline adaptive experiences show that tumor volumes and lung anatomy can change during therapy. We present and analyze a novel adaptive-on-demand (AOD) workflow combining online adaptive radiation therapy (o-ART) on the ETHOS system with </span>image guided radiation therapy delivery on a Halcyon unit for conventional fractionated radiation therapy of locally advanced lung cancer (LALC).</p></div><div><h3>Methods and Materials</h3><p>We analyzed 26 patients with LALC treated with the AOD workflow, adapting weekly. We timed segments of the workflow to evaluate efficiency in a real-world clinic. Target coverage and organ at risk (OAR) doses were compared between adaptive plans (ADP) and nonadaptive scheduled plans (SCH). Planning robustness was evaluated by the frequency of preplanning goals achieved in ADP plans, stratified by tumor volume change.</p></div><div><h3>Results</h3><p>The AOD workflow was achievable within 30 minutes for most radiation fractions. Over the course of therapy, we observed an average 26.6% ± 23.3% reduction in internal target volume (ITV). Despite these changes, with o-ART, ITV and planning target volume (PTV) coverage (V100%) was 99.2% and 93.9% for all members of the cohort, respectively. This represented a 2.9% and 6.8% improvement over nonadaptive plans (<em>P</em> &lt; .05), respectively. For tumors that grew &gt;10%, V100% was 93.1% for o-ART and 76.4% for nonadaptive plans, representing a median 17.2% improvement in the PTV coverage (<em>P</em> &lt; .05). In these plans, critical OAR constraints were met 94.1% of the time, whereas in nonadaptive plans, this figure was 81.9%. This represented reductions of 1.32 Gy, 1.34 Gy, or 1.75 Gy in the heart, esophagus, and lung, respectively. The effect was larger when tumors had shrunk more than 10%. Regardless of tumor volume alterations, the PTV/ITV coverage was achieved for all adaptive plans. Exceptional cases, where dose constraints were not met, were due to large initial tumor volumes or tumor growth.</p></div><div><h3>Conclusions</h3><p>The AOD workflow is efficient and robust in responding to anatomic changes in LALC patients, providing dosimetric advantages over standard therapy. Weekly adaptation was adequate to keep pace with changes. This approach is a feasible alternative to conventional offline replanning workflows for managing anatomy changes in LALC radiation therapy.</p></div>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"14 5","pages":"Pages e395-e406"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140777547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}